1 / 7

Hiltrud Katharina Glanz Caspari Christian, cand. med. Kruchten, Anke, cand. med.

STATEMENTS 2008 on Head and Neck Cancer 1st and 2nd February 2008, Frankfurt, Germany SITE RELATED CANCER TREATMENT Oropharynx. Hiltrud Katharina Glanz Caspari Christian, cand. med. Kruchten, Anke, cand. med. Burkhardt, Ernst-Alfred Engenhart-Cabillic, Rita

lesley
Download Presentation

Hiltrud Katharina Glanz Caspari Christian, cand. med. Kruchten, Anke, cand. med.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. STATEMENTS 2008 on Head and Neck Cancer 1st and 2nd February 2008, Frankfurt, Germany SITE RELATED CANCER TREATMENT Oropharynx Hiltrud Katharina Glanz Caspari Christian, cand. med. Kruchten, Anke, cand. med. Burkhardt, Ernst-Alfred Engenhart-Cabillic, Rita Department of Otorhinolaryngology, Head and Neck Surgery and Radio-oncology, Department of statistics. University Hospital Giessen and Marburg GmbH, Campus Giessen / Germany

  2. SITE RELATED CANCER TREATMENT Oropharynx Material and Method I Unicentric retrospective study 3 years minimum follow up From 783 patients with SCC of the pharynx 673 were included to the study, mostly stage III/IV Criteria for exclusion from the study: age over 80 years severe comorbidity, synchronous malignancy, small number of therapeutical entity, incomplete therapy, treatment refused SCC of the oropharynx n= 396 SCC of the hypopharynx n= 277

  3. SITE RELATED CANCER TREATMENT Oropharynx Material and Method II oropharynx hypopharynx Surgery: n = 25 n = 27 Surgery + Radiotherapy: n = 165 n = 143 Radiotherapy: n = 108 n = 67 Prim. Chemoradiotherapy: n = 98 n = 40 396 277 Munich protocol Berlin protocol

  4. 25 surgery 165 surgery + radiotherapie 134 surgery + radiotherapie 98 chemoradio- therapie 27 surgery 67 radiotherapie 108 radiotherapie 40 chemoradio- therapie SITE RELATED CANCER TREATMENT Oropharynx Results I 5-years-survival according to method of treatment (Kaplan-Meier) SCC of the Oropharynx n= 396 SCC of the Hypopharynx n= 277

  5. SITE RELATED CANCER TREATMENT Oropharynx Results II Toxic Effects Grade III after chemoradiotherapy for SCC of the oropharynx were much higher than with radiotherapy resp. surgery alone. Persistent and progressive ulceration into the depth of the soft tissues of the neck, long lasting severe dysphagia, as well as airway-obstructing edema were observed demanding UCI-interventions.

  6. SITE RELATED CANCER TREATMENT Oropharynx Results II Toxic side effects: Persisting and progressiv ulceration, airway-obstructing edema T.H. 03.05.1952 H.S. 05.04.60 1 year after chemoradiotherapy

  7. SITE RELATED CANCER TREATMENT Oropharynx Conclusion In case of operability without major mutilation SCC of the oropharynx should be treated stillby surgery alone or surgery with postoperative radiotherapy: side-effects are low and survival rate is rather high. In contrast to the hypopharynx in advanced stages of SCC of the oropharynx primary polychemoradiotherapy has improved survival conspicuously in comparison to radiotherapy alone but toxic side effects are much higher, they can be life-threatening and often confront the head neck surgeon with major healing problems.

More Related